Opioid peptides in Parkinson's disease: effects of dopamine repletion
Identifieur interne : 002691 ( Main/Exploration ); précédent : 002690; suivant : 002692Opioid peptides in Parkinson's disease: effects of dopamine repletion
Auteurs : Fabio Baronti [États-Unis] ; Katherine E. Conant [États-Unis] ; Marianne Giuffra [États-Unis] ; Thomas L. Davis [États-Unis] ; Giorgio Brughitta [États-Unis] ; Michael J. Iadarola [États-Unis] ; Wade H. Berrettini [États-Unis] ; Thomas N. Chase [États-Unis] ; M. Maral Mouradian [États-Unis]Source :
- Brain Research [ 0006-8993 ] ; 1991.
English descriptors
- KwdEn :
Abstract
Neurotransmitters other than dopamine, including neuropeptides, could have important pathophysiologic and therapeutic roles in Parkinson's disease. Both Met-enkephalin, the main transmitter of the striatopallidal pathway, and dynorphin, one of the co-transmitters of the striatonigral pathway display complex anatomic and biochemical interactions with the basal ganglionic dopamine system. In this study, the cerebrospinal fluid content of a proenkephalin derivative, Met5 enkephalin-Arg6-Gly7-Leu8 (MERGL), was found in significantly low concentrations in parkinsonian patients following overnight withdrawal of all medications compared with control subjects, and failed to change after at least 16 h of steady-state, optimal doses of levodopa infusion intravenously. MERGL levels increased with advancing age among normal individuals but not among patients with Parkinson's disease. In contrast, dynorphin A(1–8) levels were not different between the two study groups, did not change with levodopa therapy, and failed to correlate with age or any indices of disease progression. These observations, consistent with post-mortem studies on Parkinson brains and contrary to findings in animal models of Parkinsonism, suggest that abnormality of the enkephalin system in this disease is due to involvement of these striatal neurons in the primary pathologic process.
Url:
DOI: 10.1016/0006-8993(91)91219-Q
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Opioid peptides in Parkinson's disease: effects of dopamine repletion</title><author><name sortKey="Baronti, Fabio" sort="Baronti, Fabio" uniqKey="Baronti F" first="Fabio" last="Baronti">Fabio Baronti</name></author><author><name sortKey="Conant, Katherine E" sort="Conant, Katherine E" uniqKey="Conant K" first="Katherine E." last="Conant">Katherine E. Conant</name></author><author><name sortKey="Giuffra, Marianne" sort="Giuffra, Marianne" uniqKey="Giuffra M" first="Marianne" last="Giuffra">Marianne Giuffra</name></author><author><name sortKey="Davis, Thomas L" sort="Davis, Thomas L" uniqKey="Davis T" first="Thomas L." last="Davis">Thomas L. Davis</name></author><author><name sortKey="Brughitta, Giorgio" sort="Brughitta, Giorgio" uniqKey="Brughitta G" first="Giorgio" last="Brughitta">Giorgio Brughitta</name></author><author><name sortKey="Iadarola, Michael J" sort="Iadarola, Michael J" uniqKey="Iadarola M" first="Michael J." last="Iadarola">Michael J. Iadarola</name></author><author><name sortKey="Berrettini, Wade H" sort="Berrettini, Wade H" uniqKey="Berrettini W" first="Wade H." last="Berrettini">Wade H. Berrettini</name></author><author><name sortKey="Chase, Thomas N" sort="Chase, Thomas N" uniqKey="Chase T" first="Thomas N." last="Chase">Thomas N. Chase</name></author><author><name sortKey="Maral Mouradian, M" sort="Maral Mouradian, M" uniqKey="Maral Mouradian M" first="M." last="Maral Mouradian">M. Maral Mouradian</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:F438070E36E7CAE9748D583DD0048FF238AD0BAD</idno><date when="1991" year="1991">1991</date><idno type="doi">10.1016/0006-8993(91)91219-Q</idno><idno type="url">https://api.istex.fr/document/F438070E36E7CAE9748D583DD0048FF238AD0BAD/fulltext/pdf</idno><idno type="wicri:Area/Main/Corpus">001370</idno><idno type="wicri:Area/Main/Curation">001160</idno><idno type="wicri:Area/Main/Exploration">002691</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Opioid peptides in Parkinson's disease: effects of dopamine repletion</title><author><name sortKey="Baronti, Fabio" sort="Baronti, Fabio" uniqKey="Baronti F" first="Fabio" last="Baronti">Fabio Baronti</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><placeName><region type="state">Maryland</region></placeName><wicri:cityArea>Experimental Therapeutics Branch, National Institute of Neurological Disorders and Stroke, Bethesda</wicri:cityArea></affiliation></author><author><name sortKey="Conant, Katherine E" sort="Conant, Katherine E" uniqKey="Conant K" first="Katherine E." last="Conant">Katherine E. Conant</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><placeName><region type="state">Maryland</region></placeName><wicri:cityArea>Experimental Therapeutics Branch, National Institute of Neurological Disorders and Stroke, Bethesda</wicri:cityArea></affiliation></author><author><name sortKey="Giuffra, Marianne" sort="Giuffra, Marianne" uniqKey="Giuffra M" first="Marianne" last="Giuffra">Marianne Giuffra</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><placeName><region type="state">Maryland</region></placeName><wicri:cityArea>Experimental Therapeutics Branch, National Institute of Neurological Disorders and Stroke, Bethesda</wicri:cityArea></affiliation></author><author><name sortKey="Davis, Thomas L" sort="Davis, Thomas L" uniqKey="Davis T" first="Thomas L." last="Davis">Thomas L. Davis</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><placeName><region type="state">Maryland</region></placeName><wicri:cityArea>Experimental Therapeutics Branch, National Institute of Neurological Disorders and Stroke, Bethesda</wicri:cityArea></affiliation></author><author><name sortKey="Brughitta, Giorgio" sort="Brughitta, Giorgio" uniqKey="Brughitta G" first="Giorgio" last="Brughitta">Giorgio Brughitta</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><placeName><region type="state">Maryland</region></placeName><wicri:cityArea>Experimental Therapeutics Branch, National Institute of Neurological Disorders and Stroke, Bethesda</wicri:cityArea></affiliation></author><author><name sortKey="Iadarola, Michael J" sort="Iadarola, Michael J" uniqKey="Iadarola M" first="Michael J." last="Iadarola">Michael J. Iadarola</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><placeName><region type="state">Maryland</region></placeName><wicri:cityArea>Neurobiology and Anesthesiology Branch, National Institute of Dental Research, Bethesda</wicri:cityArea></affiliation></author><author><name sortKey="Berrettini, Wade H" sort="Berrettini, Wade H" uniqKey="Berrettini W" first="Wade H." last="Berrettini">Wade H. Berrettini</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><placeName><region type="state">Maryland</region></placeName><wicri:cityArea>Clinical Neurogenetics Branch, National Institute of Mental Health, National Institutes of Health, Bethesda</wicri:cityArea></affiliation></author><author><name sortKey="Chase, Thomas N" sort="Chase, Thomas N" uniqKey="Chase T" first="Thomas N." last="Chase">Thomas N. Chase</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><placeName><region type="state">Maryland</region></placeName><wicri:cityArea>Experimental Therapeutics Branch, National Institute of Neurological Disorders and Stroke, Bethesda</wicri:cityArea></affiliation></author><author><name sortKey="Maral Mouradian, M" sort="Maral Mouradian, M" uniqKey="Maral Mouradian M" first="M." last="Maral Mouradian">M. Maral Mouradian</name><affiliation><wicri:noCountry code="subField">609.</wicri:noCountry></affiliation><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><placeName><region type="state">Maryland</region></placeName><wicri:cityArea>Experimental Therapeutics Branch, National Institute of Neurological Disorders and Stroke, Bethesda</wicri:cityArea></affiliation></author></analytic><monogr></monogr><series><title level="j">Brain Research</title><title level="j" type="abbrev">BRES</title><idno type="ISSN">0006-8993</idno><imprint><publisher>ELSEVIER</publisher><date type="published" when="1991">1991</date><biblScope unit="volume">560</biblScope><biblScope unit="issue">1–2</biblScope><biblScope unit="page" from="92">92</biblScope><biblScope unit="page" to="96">96</biblScope></imprint><idno type="ISSN">0006-8993</idno></series><idno type="istex">F438070E36E7CAE9748D583DD0048FF238AD0BAD</idno><idno type="DOI">10.1016/0006-8993(91)91219-Q</idno><idno type="PII">0006-8993(91)91219-Q</idno><idno type="ArticleID">9191219Q</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0006-8993</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Dynorphin</term><term>Enkephalin</term><term>Levodopa</term><term>Parkinson</term><term>Spinal fluid</term><term>Striatum</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Neurotransmitters other than dopamine, including neuropeptides, could have important pathophysiologic and therapeutic roles in Parkinson's disease. Both Met-enkephalin, the main transmitter of the striatopallidal pathway, and dynorphin, one of the co-transmitters of the striatonigral pathway display complex anatomic and biochemical interactions with the basal ganglionic dopamine system. In this study, the cerebrospinal fluid content of a proenkephalin derivative, Met5 enkephalin-Arg6-Gly7-Leu8 (MERGL), was found in significantly low concentrations in parkinsonian patients following overnight withdrawal of all medications compared with control subjects, and failed to change after at least 16 h of steady-state, optimal doses of levodopa infusion intravenously. MERGL levels increased with advancing age among normal individuals but not among patients with Parkinson's disease. In contrast, dynorphin A(1–8) levels were not different between the two study groups, did not change with levodopa therapy, and failed to correlate with age or any indices of disease progression. These observations, consistent with post-mortem studies on Parkinson brains and contrary to findings in animal models of Parkinsonism, suggest that abnormality of the enkephalin system in this disease is due to involvement of these striatal neurons in the primary pathologic process.</div></front></TEI><affiliations><list><country><li>États-Unis</li></country><region><li>Maryland</li></region></list><tree><country name="États-Unis"><region name="Maryland"><name sortKey="Baronti, Fabio" sort="Baronti, Fabio" uniqKey="Baronti F" first="Fabio" last="Baronti">Fabio Baronti</name></region><name sortKey="Berrettini, Wade H" sort="Berrettini, Wade H" uniqKey="Berrettini W" first="Wade H." last="Berrettini">Wade H. Berrettini</name><name sortKey="Brughitta, Giorgio" sort="Brughitta, Giorgio" uniqKey="Brughitta G" first="Giorgio" last="Brughitta">Giorgio Brughitta</name><name sortKey="Chase, Thomas N" sort="Chase, Thomas N" uniqKey="Chase T" first="Thomas N." last="Chase">Thomas N. Chase</name><name sortKey="Conant, Katherine E" sort="Conant, Katherine E" uniqKey="Conant K" first="Katherine E." last="Conant">Katherine E. Conant</name><name sortKey="Davis, Thomas L" sort="Davis, Thomas L" uniqKey="Davis T" first="Thomas L." last="Davis">Thomas L. Davis</name><name sortKey="Giuffra, Marianne" sort="Giuffra, Marianne" uniqKey="Giuffra M" first="Marianne" last="Giuffra">Marianne Giuffra</name><name sortKey="Iadarola, Michael J" sort="Iadarola, Michael J" uniqKey="Iadarola M" first="Michael J." last="Iadarola">Michael J. Iadarola</name><name sortKey="Maral Mouradian, M" sort="Maral Mouradian, M" uniqKey="Maral Mouradian M" first="M." last="Maral Mouradian">M. Maral Mouradian</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002691 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 002691 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:F438070E36E7CAE9748D583DD0048FF238AD0BAD
|texte= Opioid peptides in Parkinson's disease: effects of dopamine repletion
}}
| This area was generated with Dilib version V0.6.23. |  |